JP7655860B2 - ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物 - Google Patents

ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物 Download PDF

Info

Publication number
JP7655860B2
JP7655860B2 JP2021568005A JP2021568005A JP7655860B2 JP 7655860 B2 JP7655860 B2 JP 7655860B2 JP 2021568005 A JP2021568005 A JP 2021568005A JP 2021568005 A JP2021568005 A JP 2021568005A JP 7655860 B2 JP7655860 B2 JP 7655860B2
Authority
JP
Japan
Prior art keywords
biotin moiety
seq
group
cysteine
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021568005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535685A (ja
JP2022535685A5 (https=
JPWO2020242268A5 (https=
Inventor
ジェヒ シン，
オク－チョル チョン，
ウン ジ パク，
Original Assignee
ディーアンドディー ファーマテック インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディーアンドディー ファーマテック インコーポレイテッド filed Critical ディーアンドディー ファーマテック インコーポレイテッド
Priority claimed from KR1020200065484A external-priority patent/KR102480393B1/ko
Publication of JP2022535685A publication Critical patent/JP2022535685A/ja
Publication of JP2022535685A5 publication Critical patent/JP2022535685A5/ja
Publication of JPWO2020242268A5 publication Critical patent/JPWO2020242268A5/ja
Priority to JP2025020196A priority Critical patent/JP2025065438A/ja
Application granted granted Critical
Publication of JP7655860B2 publication Critical patent/JP7655860B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2021568005A 2019-05-31 2020-05-29 ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物 Active JP7655860B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025020196A JP2025065438A (ja) 2019-05-31 2025-02-10 ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190064370 2019-05-31
KR10-2019-0064370 2019-05-31
PCT/KR2020/007053 WO2020242268A1 (ko) 2019-05-31 2020-05-29 비오틴 모이어티와 결합된 생리활성 물질 및 이를 포함하는 경구 투여용 조성물
KR1020200065484A KR102480393B1 (ko) 2019-05-31 2020-05-29 비오틴 모이어티와 결합된 생리활성 물질 및 이를 포함하는 경구 투여용 조성물
KR10-2020-0065484 2020-05-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025020196A Division JP2025065438A (ja) 2019-05-31 2025-02-10 ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物

Publications (4)

Publication Number Publication Date
JP2022535685A JP2022535685A (ja) 2022-08-10
JP2022535685A5 JP2022535685A5 (https=) 2023-06-05
JPWO2020242268A5 JPWO2020242268A5 (https=) 2023-06-05
JP7655860B2 true JP7655860B2 (ja) 2025-04-02

Family

ID=73551925

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568005A Active JP7655860B2 (ja) 2019-05-31 2020-05-29 ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物
JP2025020196A Pending JP2025065438A (ja) 2019-05-31 2025-02-10 ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025020196A Pending JP2025065438A (ja) 2019-05-31 2025-02-10 ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物

Country Status (4)

Country Link
US (1) US20230000834A1 (https=)
JP (2) JP7655860B2 (https=)
CA (1) CA3142322A1 (https=)
WO (1) WO2020242268A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107900A1 (en) 2008-02-25 2009-09-03 Sungkyunkwan University Foundation For Corporate Collaboration Exendin derivative linked biotin, method for the preparation thereof and pharmaceutical composition comprising the same
JP2014527801A (ja) 2011-09-01 2014-10-23 ユニバーシティ オブ サザン カリフォルニア ハイスループットペプチドミメティックを調製するための方法、経口バイオアベイラブルな薬物およびそれを含有する組成物
US20150011246A1 (en) 2013-07-03 2015-01-08 Qualcomm Incorporated Systems and methods for labeling crowd sourced data

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141676B1 (en) * 1996-02-08 2006-11-28 University Of Washington Water soluble multi-biotin-containing compounds
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR20160110762A (ko) * 2015-03-12 2016-09-22 주식회사 레모넥스 생리활성물질 전달을 위한 탄소나노입자-고분자 복합체의 합성과 이의 용도
CN109485655B (zh) * 2018-12-20 2021-06-25 河北百灵威超精细材料有限公司 一种生物素马来酰亚胺的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107900A1 (en) 2008-02-25 2009-09-03 Sungkyunkwan University Foundation For Corporate Collaboration Exendin derivative linked biotin, method for the preparation thereof and pharmaceutical composition comprising the same
JP2014527801A (ja) 2011-09-01 2014-10-23 ユニバーシティ オブ サザン カリフォルニア ハイスループットペプチドミメティックを調製するための方法、経口バイオアベイラブルな薬物およびそれを含有する組成物
US20150011246A1 (en) 2013-07-03 2015-01-08 Qualcomm Incorporated Systems and methods for labeling crowd sourced data

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Cheng-Hao JIN et al.，"A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice"，Journal of Controlled Release，2009年02月，Vol. 133, No. 3，p.172-177，DOI: 10.1016/j.jconrel.2008.09.091
E．J. VERSPOHL，"Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors"，Pharmacology & Therapeutics，2009年10月，Vol. 124, No. 1，p.113-138，DOI: 10.1016/j.pharmthera.2009.06.002
FRIESEN,H.J. et al，Novel maleimido-biotins for the selective biotinylation of sulfhydryls，Protides of the Biological Fluids，1986年，Vol.34，pp.43-46
Kathleen Corey FLANDERS et al.，"Semisynthetic derivatives of glucagon: (Des-His1)N.epsilon.-acetimidoglucagon and N.alpha.-biotinyl-N.epsilon.-acetimidoglucagon"，Biochemistry，1982年08月01日，Vol. 21, No. 18，p.4244-4251，DOI: 10.1021/bi00261a010
Meltem CETIN et al.，"Preparation and Characterization of Salmon Calcitonin-biotin Conjugates"，AAPS PharmSciTech，2008年12月，Vol. 9, No. 4，p.1191-1197，DOI: 10.1208/s12249-008-9165-2
Serena SINGH et al.，"Self-Assembly of a Functional Triple Protein: Hemoglobin-Avidin-Hemoglobin via Biotin-Avidin Interactions"，Biochemistry，2016年05月05日，Vol. 55, No. 20，p.2875-2882，DOI: 10.1021/acs.biochem.6b00215
Su Young CHAE et al.，"Preparation, Characterization, and Application of Biotinylated and Biotin-PEGylated Glucagon-Like Peptide-1 Analogues for Enhanced Oral Delivery"，Bioconjugate Chemistry，2007年12月14日，Vol. 19, No. 1，p.334-341，DOI: 10.1021/bc700292v
Y YOUN，"Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: Design, preparation, and biological evaluation"，European Journal of Pharmaceutics and Biopharmaceutics，2008年03月，Vol. 68, No. 3，p.667-675，DOI: 10.1016/j.ejpb.2007.07.009

Also Published As

Publication number Publication date
JP2022535685A (ja) 2022-08-10
WO2020242268A1 (ko) 2020-12-03
CA3142322A1 (en) 2020-12-03
US20230000834A1 (en) 2023-01-05
JP2025065438A (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
JP6585197B2 (ja) グルカゴン及びｇｌｐ−１共アゴニスト化合物
JP2021138740A (ja) Ｇｉｐアゴニスト化合物及び方法
CN110845601B (zh) 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
JP2014510735A (ja) 部位特異的モノｐｅｇ化エキセンジン類似体およびその調製方法
KR102480393B1 (ko) 비오틴 모이어티와 결합된 생리활성 물질 및 이를 포함하는 경구 투여용 조성물
WO2025073222A1 (zh) Glp-1r/gipr/gcgr三重激动剂类似物及其用途
CN104945499B (zh) 结构修饰的glp-1类似物及其制备方法
JP2025065438A (ja) ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物
KR20080065622A (ko) 안정화된 혈액내 전달을 위한 생리활성 기질 전달체, 이를포함하는 복합체 및 이를 이용한 생리활성 기질의 혈액내전달 방법
RU2854617C2 (ru) Конъюгат биологически активного материала, содержащий фрагмент биотина, фрагмент жирной кислоты или их комбинацию, связанную с ним
RU2860768C2 (ru) Пероральный состав конъюгата биологически активного материала, содержащего фрагмент биотина, фрагмент жирной кислоты или их комбинацию, связанную с ним
AU2021386899B2 (en) Biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
AU2021385222B2 (en) Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
CN116589536B (zh) 一类长效glp-1/gip受体双重激动剂及其应用
CA3043151C (en) Acylated glp-1/glp-2 dual agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250310

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250321

R150 Certificate of patent or registration of utility model

Ref document number: 7655860

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150